FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q90115232> ?p ?o ?g. }

• Q90115232 description "artículu científicu espublizáu en marzu de 2020" @default.
• Q90115232 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
• Q90115232 description "scientific article published on 6 March 2020" @default.
• Q90115232 description "wetenschappelijk artikel" @default.
• Q90115232 description "наукова стаття, опублікована 6 березня 2020" @default.
• Q90115232 description "գիտական հոդված հրատարակված 2020 թվականի մարտի 6-ին" @default.
• Q90115232 name "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 name "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 type Item @default.
• Q90115232 label "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 label "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 prefLabel "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 prefLabel "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 P1433 Q90115232-02DE60FA-B67F-47FB-9DDD-3E5A04FAEB9A @default.
• Q90115232 P1476 Q90115232-1B7BE8B2-81A7-410C-824F-A879FF39E0E0 @default.
• Q90115232 P2093 Q90115232-1B934F7C-208B-48FA-A52C-3A33D85D002D @default.
• Q90115232 P2093 Q90115232-3FF2FAAC-F68A-4DBB-AF2A-F8BCAE9B932E @default.
• Q90115232 P2093 Q90115232-96C2AF7B-8DC0-4AA3-A98C-93543C296A47 @default.
• Q90115232 P2093 Q90115232-BC694739-9F6C-4035-AAE5-5C2F2BB23CCF @default.
• Q90115232 P2093 Q90115232-F2B6FFAE-F255-4D78-9213-721F838B3642 @default.
• Q90115232 P2093 Q90115232-F4A172F5-0766-4614-A450-5E8FE347B460 @default.
• Q90115232 P2860 Q90115232-0763793D-C15A-4E2F-BC17-F4BFD77DA0A1 @default.
• Q90115232 P2860 Q90115232-0E3B3DDF-6394-4193-ACA2-A9BD2604E511 @default.
• Q90115232 P2860 Q90115232-1198CF91-ADEC-42E1-B69E-2782858A162D @default.
• Q90115232 P2860 Q90115232-13A8806E-7794-4ADA-8D44-23CE60FE8A42 @default.
• Q90115232 P2860 Q90115232-16526869-31D9-4142-B32C-683077D34CEF @default.
• Q90115232 P2860 Q90115232-1A62E612-F7D6-4D78-AE54-9D0AECFFC99C @default.
• Q90115232 P2860 Q90115232-235F754E-DBF9-4B82-BD05-08EAF0EFD18F @default.
• Q90115232 P2860 Q90115232-24207497-B8E3-426D-8C02-84F110F47821 @default.
• Q90115232 P2860 Q90115232-24799EC1-651D-4768-B91B-7ABF95BF2277 @default.
• Q90115232 P2860 Q90115232-2C1A313A-3C6F-4E6F-A896-0661DFC3B945 @default.
• Q90115232 P2860 Q90115232-357B7313-BD2E-451F-8772-542AFFFD7F02 @default.
• Q90115232 P2860 Q90115232-3AEA20F7-B7B2-4A31-85B6-6C8C3F3C23EF @default.
• Q90115232 P2860 Q90115232-3BE941CE-BAA9-4006-BC46-B6899FDC6D3E @default.
• Q90115232 P2860 Q90115232-3C1CA2F8-022D-4A99-93A3-2C13550AE018 @default.
• Q90115232 P2860 Q90115232-40FBDBDD-AF13-4E3A-8116-A5425AADD0AB @default.
• Q90115232 P2860 Q90115232-4EFC757B-AC73-4B64-B629-DE93FF03DFB4 @default.
• Q90115232 P2860 Q90115232-52B1DE49-03D5-404B-8C87-C3FEB8B075C0 @default.
• Q90115232 P2860 Q90115232-5CF64EEF-8300-475E-BB7F-FB4A87D311F6 @default.
• Q90115232 P2860 Q90115232-69B4BE80-CE69-401F-8B90-5ACCD22F59EA @default.
• Q90115232 P2860 Q90115232-75FE9DCA-DF32-417C-BCCC-93518B4E1F29 @default.
• Q90115232 P2860 Q90115232-780A0AD8-4FBC-4CDD-8B82-F4014F33A697 @default.
• Q90115232 P2860 Q90115232-9561EBF2-B42F-4725-A0A1-14C533750317 @default.
• Q90115232 P2860 Q90115232-969E0E8D-B8B1-44E5-96B8-91B12F5FB005 @default.
• Q90115232 P2860 Q90115232-988F8E04-A68C-4056-973C-87869AAB7191 @default.
• Q90115232 P2860 Q90115232-9A2CB241-D798-4E25-BA6E-6A46B26E9251 @default.
• Q90115232 P2860 Q90115232-9F17D578-05AC-4CDE-97A5-C5C6C6B0D674 @default.
• Q90115232 P2860 Q90115232-A7E78453-4682-4605-ACDC-8D44905A954B @default.
• Q90115232 P2860 Q90115232-A925DDC5-CF7B-47FD-B51D-00E70FAE641D @default.
• Q90115232 P2860 Q90115232-AA547023-3338-441C-8357-0D36715084E2 @default.
• Q90115232 P2860 Q90115232-AD9D77B2-421C-4593-829E-50BDE9137560 @default.
• Q90115232 P2860 Q90115232-BD69702E-4D15-4778-9817-12232C7434A4 @default.
• Q90115232 P2860 Q90115232-BFDAE9F0-2018-48FA-BA20-691AA5A14308 @default.
• Q90115232 P2860 Q90115232-CA946B73-D40A-48FF-AEAA-C32C0EF0FBF8 @default.
• Q90115232 P2860 Q90115232-DF5F2E7C-97D0-4A1C-A88F-BAC1CFA48363 @default.
• Q90115232 P2860 Q90115232-EF57E08B-B5C8-4DB5-89E8-ADE24E8B4DCB @default.
• Q90115232 P2860 Q90115232-F03664CC-F522-45E3-BCD5-A84CA4CE4BF7 @default.
• Q90115232 P2860 Q90115232-FAA953B8-4123-4CC9-90E9-68EB55273999 @default.
• Q90115232 P304 Q90115232-44C10E7E-696D-4CAB-8E33-7C391184C972 @default.
• Q90115232 P31 Q90115232-E5CD7149-215D-4670-8F6F-DE2CCD49D4F2 @default.
• Q90115232 P356 Q90115232-9274C244-8794-4BC2-9CFA-7DCEBFA017B7 @default.
• Q90115232 P433 Q90115232-923ED8BC-1A22-4C14-96F9-096AA3AF3CE6 @default.
• Q90115232 P478 Q90115232-C6277B87-6AEF-4AAC-AC65-78915576DE52 @default.
• Q90115232 P50 Q90115232-44534E70-C066-4CF8-998D-27E2EF57ADFB @default.
• Q90115232 P50 Q90115232-A0642C4A-6984-40A4-B1BA-AF3D224337CC @default.
• Q90115232 P50 Q90115232-AF88C2FA-E68F-46DB-BE5F-531F6429EFA6 @default.
• Q90115232 P577 Q90115232-C976B64A-EB9F-410C-88AF-15C12AB6A8D3 @default.
• Q90115232 P698 Q90115232-4DB65D58-B387-48B7-A3AB-31601699A92E @default.
• Q90115232 P921 Q90115232-3A3C2961-7B69-4C6B-9080-9D35730DA47B @default.
• Q90115232 P921 Q90115232-5E6F88C6-58B4-4E74-BD89-4137883F40F4 @default.
• Q90115232 P921 Q90115232-79DDD414-292E-4407-854F-76CFB04580E7 @default.
• Q90115232 P921 Q90115232-8B66ACAF-A778-4A14-9FC7-C1ABEA02F4E7 @default.
• Q90115232 P932 Q90115232-8BF16FC8-3543-4CC1-BD07-60DCB7C6BEED @default.
• Q90115232 P356 S13075-020-2126-1 @default.
• Q90115232 P698 32143685 @default.
• Q90115232 P1433 Q15757229 @default.
• Q90115232 P1476 "Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial" @default.
• Q90115232 P2093 "Diane D Harrison" @default.
• Q90115232 P2093 "Elizabeth C Hsia" @default.
• Q90115232 P2093 "Kim Hung Lo" @default.
• Q90115232 P2093 "Shelly Kafka" @default.
• Q90115232 P2093 "Soumya D Chakravarty" @default.
• Q90115232 P2093 "Stephen Xu" @default.
• Q90115232 P2860 Q30677867 @default.
• Q90115232 P2860 Q33213855 @default.
• Q90115232 P2860 Q33805455 @default.
• Q90115232 P2860 Q34690752 @default.
• Q90115232 P2860 Q34967810 @default.
• Q90115232 P2860 Q36040076 @default.
• Q90115232 P2860 Q36550827 @default.
• Q90115232 P2860 Q37207025 @default.
• Q90115232 P2860 Q38134128 @default.
• Q90115232 P2860 Q38691418 @default.
• Q90115232 P2860 Q40095048 @default.
• Q90115232 P2860 Q40209854 @default.
• Q90115232 P2860 Q40705952 @default.
• Q90115232 P2860 Q41478116 @default.
• Q90115232 P2860 Q46415476 @default.
• Q90115232 P2860 Q46436416 @default.
• Q90115232 P2860 Q46582955 @default.

• next